Fruquintinib | List of Frontiers open access articles

Original Research

Published on 11 Mar 2025

Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Qinqin Song
Hongjiao Wu
Ye Jin
Junzhi Hou
Jiawei Liu
Xuemei Zhang
Wanning Hu
Guogui Sun
Zhi Zhang

Frontiers in Oncology

doi 10.3389/fonc.2025.1503133

3,763 views
5 citations

Original Research

Published on 17 Mar 2022

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

in Cancer Molecular Targets and Therapeutics

Qingli Li
Xiaojiao Cheng
Cong Zhou
Yao Tang
Fuli Li
Baiwen Zhang
Tinglei Huang
Jianzheng Wang
Shuiping Tu

Frontiers in Oncology

doi 10.3389/fonc.2022.841977

11,110 views
46 citations

Original Research

Published on 16 Jul 2025

The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study

in Cancer Immunity and Immunotherapy

Yao Wang
Du Meilu
Shi Qi
Tang Yufei
Gao Song
Han Susu
Wen Haotian
Zhu Tingting
Wang Chao
Hou Fenggang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1582308

3,983 views
1 citation

Original Research

Published on 03 Mar 2023

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

in Gastrointestinal Cancers: Colorectal Cancer

Ya-Ya Deng
Xin-Yue Zhang
Peng-Fei Zhu
Hong-Rui Lu
Qian Liu
Shuang-Yue Pan
Zhe-Ling Chen
Liu Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1097911

11,952 views
26 citations

Case Report

Published on 28 Jun 2023

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Ruiqi Wang
Dan Cong
Yuansong Bai
Wenlong Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1207369

4,959 views
3 citations

Case Report

Published on 05 Jul 2021

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer

in Pharmacology of Anti-Cancer Drugs

Yefei Shu
Song Zheng

Frontiers in Oncology

doi 10.3389/fonc.2021.688231

4,719 views
3 citations

Original Research

Published on 24 Nov 2022

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer

in Gastrointestinal Cancers: Colorectal Cancer

Ying Jin
Jin Li
Lin Shen
Jianming Xu
Yanqiao Zhang
Jingdong Zhang
Hongming Pan
Xiujuan Qu
Yamin Chen
Qiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1044328

7,241 views
6 citations

Original Research

Published on 11 Dec 2025

Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations

in Cancer Immunity and Immunotherapy

Lucía Suárez
María Martínez-Azcona
Irantzu Serrano-Mendioroz
Leticia Fernández-Rubio
María Esperanza Rodríguez-Ruiz
Ana Rouzaut

Frontiers in Immunology

doi 10.3389/fimmu.2025.1699980

1,862 views

Study Protocol

Accepted on 28 Apr 2026

Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial

in Cancer Immunity and Immunotherapy

Zhenyu Ma
Kunli Zhu
Fang Shi
Rui Feng
Shumei Jiang
Xue Dou
Jing Liu
Zuoxing Niu
Jinbo Yue

Frontiers in Immunology

231 views

Original Research

Published on 02 Dec 2024

A real-world study: third-line treatment options for metastatic colorectal cancer

in Molecular and Cellular Oncology

Chen Wu
Shuai Li
Xinfang Hou

Frontiers in Oncology

doi 10.3389/fonc.2024.1480704

6,328 views
4 citations

Original Research

Published on 13 Nov 2020

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies

in Gastrointestinal Cancers

Lei Wang
Huijiao Cao
Chang Jiang
Wenzhuo He
Yafei You
Kunwei Peng
Yanan Jin
Liangping Xia

Frontiers in Oncology

doi 10.3389/fonc.2020.587692

4,676 views
6 citations

Case Report

Published on 17 Apr 2025

SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review

in Cancer Immunity and Immunotherapy

Jie Dong
Jinli Zhang
Hongming Pan
Chongwei Wang
Jin Sheng

Frontiers in Immunology

doi 10.3389/fimmu.2025.1521828

5,354 views
2 citations

Case Report

Published on 12 Mar 2026

Duodenal and cutaneous metastases from advanced rectal cancer: a rare case report

in Gastrointestinal Cancers: Colorectal Cancer

Jiaoling He
Yun Lin
Sikai Chen
Tingfang Zuo
Feilai Xie
Yan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2026.1754861

390 views

Original Research

Published on 26 Sep 2022

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

in Gastrointestinal Cancers: Colorectal Cancer

Caiyun Nie
Huifang Lv
Beibei Chen
Weifeng Xu
Jianzheng Wang
Yingjun Liu
Saiqi Wang
Jing Zhao
Yunduan He
Xiaobing Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.917353

6,319 views
22 citations

Original Research

Published on 20 Aug 2024

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy

in Cancer Imaging and Image-directed Interventions

Kanglian Zheng
Xu Zhu
Liang Xu
Guang Cao
Chuanxin Niu
Xiaoluan Yan
Da Xu
Wei Liu
Quan Bao
Lijun Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1420956

4,333 views
5 citations

Mini Review

Published on 24 May 2021

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review

in Gastrointestinal Cancers

Yong Li
Xian Chen
Wenzhu Li
Yongsong Ye
Xiaohua Du
Shaodan Sun
Lirong Liu
Haibo Zhang

Frontiers in Oncology

doi 10.3389/fonc.2021.684309

10,593 views
24 citations

Articles

Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer

Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations

Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial

A real-world study: third-line treatment options for metastatic colorectal cancer

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies

SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review

Duodenal and cutaneous metastases from advanced rectal cancer: a rare case report

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review